Tags

Type your tag names separated by a space and hit enter

The underutilization of intrathecal baclofen in poststroke spasticity.
Top Stroke Rehabil. 2011 May-Jun; 18(3):195-202.TS

Abstract

Stroke is one of the leading causes of adult disability in the United States, with a reported prevalence of 6.4 million people. Spasticity is one of the clinical features of the upper motor neuron syndrome seen after a stroke. The prevalence of spasticity after a stroke ranges from 17% to 42.6%, and an average of two-thirds of people with spasticity have upper and lower extremity involvement. Oral medications and botulinum neurotoxin injections are current treatments for problematic spasticity. However, these treatments are often limited by side effects or dose ceilings. Intrathecal baclofen (ITB) is a proven method for the management of disabling spasticity from multiple etiologies. Studies have demonstrated improved mobility, activities of daily living, and quality of life in spastic poststroke patients. Despite the benefits of ITB, fewer than 1% of stroke patients with severe disabling spasticity are being treated with ITB. This article will review the prevalence of severe poststroke spasticity and the rate of ITB use and will discuss reasons for its limited use in stroke survivors.

Authors+Show Affiliations

Aurora Medical Center Summit, Summit, Wisconsin, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21642057

Citation

Dvorak, Eric M., et al. "The Underutilization of Intrathecal Baclofen in Poststroke Spasticity." Topics in Stroke Rehabilitation, vol. 18, no. 3, 2011, pp. 195-202.
Dvorak EM, Ketchum NC, McGuire JR. The underutilization of intrathecal baclofen in poststroke spasticity. Top Stroke Rehabil. 2011;18(3):195-202.
Dvorak, E. M., Ketchum, N. C., & McGuire, J. R. (2011). The underutilization of intrathecal baclofen in poststroke spasticity. Topics in Stroke Rehabilitation, 18(3), 195-202. https://doi.org/10.1310/tsr1803-195
Dvorak EM, Ketchum NC, McGuire JR. The Underutilization of Intrathecal Baclofen in Poststroke Spasticity. Top Stroke Rehabil. 2011 May-Jun;18(3):195-202. PubMed PMID: 21642057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The underutilization of intrathecal baclofen in poststroke spasticity. AU - Dvorak,Eric M, AU - Ketchum,Nicholas C, AU - McGuire,John R, PY - 2011/6/7/entrez PY - 2011/6/7/pubmed PY - 2011/7/13/medline SP - 195 EP - 202 JF - Topics in stroke rehabilitation JO - Top Stroke Rehabil VL - 18 IS - 3 N2 - Stroke is one of the leading causes of adult disability in the United States, with a reported prevalence of 6.4 million people. Spasticity is one of the clinical features of the upper motor neuron syndrome seen after a stroke. The prevalence of spasticity after a stroke ranges from 17% to 42.6%, and an average of two-thirds of people with spasticity have upper and lower extremity involvement. Oral medications and botulinum neurotoxin injections are current treatments for problematic spasticity. However, these treatments are often limited by side effects or dose ceilings. Intrathecal baclofen (ITB) is a proven method for the management of disabling spasticity from multiple etiologies. Studies have demonstrated improved mobility, activities of daily living, and quality of life in spastic poststroke patients. Despite the benefits of ITB, fewer than 1% of stroke patients with severe disabling spasticity are being treated with ITB. This article will review the prevalence of severe poststroke spasticity and the rate of ITB use and will discuss reasons for its limited use in stroke survivors. SN - 1074-9357 UR - https://www.unboundmedicine.com/medline/citation/21642057/The_underutilization_of_intrathecal_baclofen_in_poststroke_spasticity_ L2 - https://www.tandfonline.com/doi/full/10.1310/tsr1803-195 DB - PRIME DP - Unbound Medicine ER -